Aperçu: G.M.
Le système sérotoninergique lié à l'ocytocine (OT) est considéré comme
jouant un rôle important dans l'étiologie et les symptômes sociaux du trouble
du spectre de l'autisme (TSA). Cependant,
aucune preuve n'existe sur la relation entre l'effet prosocial de
l'administration chronique de l'OT et le système sérotoninergique du
cerveau. Dix
sujets masculins avec un diagnostic de TSA ont été reçu de l'OT pendant 8 à 10
semaines sous une forme ouverte, monoparentale, non randomisée et non
contrôlée.
Avant et pendant le traitement de l'OT, la tomographie par émission de positons a été utilisée
Ensuite, la liaison du transporteur de sérotonine (11C-DASB BPND) a été estimée. Les
principaux résultats ont été les changements dans le BPND 11C-DASB et
les changements dans la réponse émotionnelle aux visages des autres.
Aucun
changement significatif n'a été trouvé dans la réponse émotionnelle aux
visages des autres après le traitement de l'OT de 8 à 10 semaines. Cependant,
l'augmentation du niveau de transporteur de sérotonine (SERT) dans le
striatum après le traitement a été corrélé de manière significative avec
une augmentation de la réponse émotionnelle négative aux visages
humains.
Cette
étude a révélé une relation entre les changements dans le système
sérotoninergique et la prosocialité après administration de
l'OT.
Psychiatry Res. 2017 Jun 28;267:45-50. doi: 10.1016/j.pscychresns.2017.06.015.
Oxytocin effects on emotional response to others' faces via serotonin system in autism: A pilot study
Fukai M1, Hirosawa T2, Kikuchi M3, Ouchi Y4, Takahashi T5, Yoshimura Y5, Miyagishi Y1, Kosaka H6, Yokokura M7, Yoshikawa E8, Bunai T4, Minabe Y3.
Author information
- 1
- Department of Psychiatry and Neurobiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
- 2
- Department of Psychiatry and Neurobiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan. Electronic address: hirosawatetsu1982@yahoo.co.jp.
- 3
- Department of Psychiatry and Neurobiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan; Research Center for Child Mental Development, Kanazawa University, Kanazawa, Japan.
- 4
- Department of Biofunctional Imaging, Medical Photonics Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- 5
- Research Center for Child Mental Development, Kanazawa University, Kanazawa, Japan.
- 6
- Research Center for Child Mental Development, University of Fukui, Japan.
- 7
- Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- 8
- Central Research Laboratory, Hamamatsu Photonics KK, Hamamatsu, Japan.
Abstract
The
oxytocin (OT)-related serotonergic system is thought to play an
important role in the etiology and social symptoms of autism spectrum
disorder (ASD). However, no evidence exists for the relation between the
prosocial effect of chronic OT administration and the brain
serotonergic system. Ten male subjects with ASD were administered OT for
8-10 weeks in an open-label, single-arm, non-randomized, uncontrolled
manner. Before and during the OT treatment, positron emission tomography
was used with the (11C)-3-amino-4-(2-[(demethylamino)methyl]phenylthio)benzonitrile(11C-DASB) radiotracer. Then binding of serotonin transporter (11C-DASB BPND) was estimated. The main outcome measures were changes in 11C-DASB BPND
and changes in the emotional response to others' faces. No significant
change was found in the emotional response to others' faces after the
8-10 week OT treatment. However, the increased serotonin transporter
(SERT) level in the striatum after treatment was correlated
significantly with increased negative emotional response to human faces.
This study revealed a relation between changes in the serotonergic
system and in prosociality after chronic OT administration. Additional
studies must be conducted to verify the chronic OT effects on social
behavior via the serotonergic system.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.
- PMID:28738293
- DOI:10.1016/j.pscychresns.2017.06.015